Abstract
Thalassemia and hemoglobinopathies necessitate lifelong disease management, leading to significant treatment costs. Generic medications offer potential cost savings, but concerns persist regarding their comparative effectiveness and safety compared to brand-name drugs. This comprehensive review evaluates the evidence concerning the utilization of generics for transfusion-dependent thalassemia and hemoglobinopathies. Quality-assured generics can offer substantial cost savings for both health systems and patients, contingent upon ensuring bioequivalence, efficacy, pharmacovigilance, and addressing stakeholder concerns.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
